Guardant Reveal
A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.
Overview
Guardant Reveal launched in 2021 as the first tissue-free MRD test, initially for stage II-III colorectal cancer, with Medicare coverage for colorectal cancer surveillance and later breast and lung indications. Tumour-naive design gives a result within about a week of surgery and suits patients whose tissue is unavailable, at the cost of somewhat lower sensitivity than bespoke tumour-informed panels such as Signatera. Published colorectal data show ctDNA positivity after surgery carries a high risk of recurrence, and serial negative results are strongly reassuring. It is a laboratory-developed test under CLIA.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: ctDNA detected after surgery means a high chance of recurrence and a case for closer follow-up or adjuvant therapy; not detected is reassuring but not a guarantee.
Latest papers
topQuery for this drug: (TITLE:"Guardant Reveal" OR ABSTRACT:"Guardant Reveal") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Guardant Reveal, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductOncodetect
Shares Signatera, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag test.
- ProductResolution ctDx FIRST
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
- ProductGuardant360 CDx
Shares Guardant Health, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer and the tag test.
- Productcobas EGFR Mutation Test v2
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
- ProductMI Cancer Seek
Shares Colorectal cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.
- ProductSimpleScreen CRC
Shares DNA methylation profiling, Liquid biopsy (ctDNA), Colorectal cancer and the tag test.
- ProductCancerguard
Shares DNA methylation profiling, Liquid biopsy (ctDNA) and the tag test.
- ProductclonoSEQ
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag test.